Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
05 mai 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference
05 avr. 2022 16h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
05 avr. 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal
17 mars 2022 09h00 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference
08 mars 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance
01 mars 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors
17 févr. 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February
11 févr. 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022
07 févr. 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Appoints Prathyusha Duraibabu to Board of Directors
22 nov. 2021 07h00 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...